Skip to content
Home/Companies/MedTech/Diesse
Diesse

Diesse

MedTech·Italy·Exited 2025·Held 6yr
Entry
2019
Hold
6yr
Exit
2025

Who owns Diesse?

Diesse is an Italian MedTech company, now owned by Fremman Capital, which acquired it in 2025 from ARCHIMED.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
ARCHIMED
Investor
ARCHIMED
MED II · 2017 · Buyout

Key facts

HQItaly
SectorMedTech
Websitewww.diesse.it
Key takeaways
  • ·Fully exited in 2025 to Fremman Capital.
  • ·Best return: 4.6x MOIC by ARCHIMED (2025 exit).
Exit Type
Secondary
Buyer
Fremman Capital
MOIC
4.6x
Exit Year
2025

More from MED II

Other portfolio companies in the same fund.

Ceva Sante Animale
Ceva Sante Animale
Active
PharmaFrance· 2025
Clean Biologics
Clean Biologics
Exited 2024
BiotechFrance· 2018
to MED Bio
Provepharm
Provepharm
Active
BiotechFrance· 2018
Soest Medical Group
Soest Medical Group
Active
MedTechThe Netherlands· 2018

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany

Questions

Who owns Diesse?

Diesse is now owned by Fremman Capital, which acquired it in 2025 from ARCHIMED.

When did Fremman Capital acquire Diesse?

Fremman Capital acquired Diesse in 2025, buying from ARCHIMED.

Who did Diesse sell to?

ARCHIMED sold Diesse to Fremman Capital in 2025 (Secondary), 4.6x return.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue